Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$20.5K Sell
180
-7
-4% -$825 ﹤0.01% 2025
2026
Q2
$19.9K Buy
187
+10
+6% +$1.21K ﹤0.01% 2022
2026
Q1
$28.9K Sell
177
-22
-11% -$3.38K ﹤0.01% 1555
2025
Q4
$34.6K Sell
199
-17
-8% -$3.1K ﹤0.01% 1516
2025
Q3
$31.1K Buy
216
+7
+3% +$858 ﹤0.01% 1377
2025
Q2
$21K Buy
209
+36
+21% +$2.75K ﹤0.01% 1476
2025
Q1
$13.2K Buy
173
+17
+11% +$1.3K ﹤0.01% 1641
2024
Q4
$10.8K Sell
156
-5
-3% -$360 ﹤0.01% 1733
2024
Q3
$11.8K Buy
+161
New +$11.9K ﹤0.01% 1676

Other funds holding INSM

BFC Planning's INSM Position: Q3 2026 in Review

BFC Planning reduced its Insmed (INSM) stake by 3.7% in Q3 2026, selling an estimated $825 and leaving 180 shares worth $20.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2025.

BFC Planning first reported a position in INSM in Q3 2024 and has held it in 9 quarters since. The position peaked at $34.6K in Q4 2025. 568 funds tracked by Wall St. Rank hold INSM as of Q3 2026.

  • BFC Planning held 180 shares of Insmed worth $20.5K as of Q3 2026.
  • BFC Planning sold 7 Insmed shares in Q3 2026, an estimated $825.
  • Insmed made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2025 holding.
  • BFC Planning first reported a position in Insmed in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Insmed position peaked at $34.6K in Q4 2025.
  • 568 funds tracked by Wall St. Rank held Insmed as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.